Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vancomycin

FDA-approved product (solution, intravenous, oral), marketed as Vancomycin, Firvanq Kit, Tyzavan and 5 more.

Registered studies
50+
Lab records
118
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vancomycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Diarrhea
  • Endocarditis
  • Enterocolitis
  • Eye infection
  • Infection
  • Infective endocarditis
  • Respiratory tract infectious disorder
  • Sepsis
  • Skin disease
  • Skin infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics; Glycopeptide antibacterials
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XA01; WHO ATC A07AA09; WHO ATC S01AA28

Repurposing investigation

Vancomycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli78.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae80.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis14.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 103 of 103 lab records
  • E. coli: measured active in 8 of 9 lab records
  • K. pneumoniae: measured active in 2 of 3 lab records
  • M. tuberculosis: measured active in 0 of 3 lab records
Open Vancomycin in ChEMBL Registered studies below
Show the 118 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vancomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • IO Vancomycin Administration in TKA

    NCT07633418 · start 2026-06-01

    Registered record
    Registry ID
    NCT07633418
    Conditions
    Total Knee Arthroplasty
    Interventions
    Intraosseous Vamcomycin Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-06-01
    Completion
    2029-04-29
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTotal Knee Arthroplasty
    InterventionIntraosseous Vamcomycin Administration
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Ulcerative Colitis on Advanced Therapies

    NCT06906445 · start 2025-03-15

    Registered record
    Registry ID
    NCT06906445
    Conditions
    Ulcerative Colitis
    Interventions
    Fecal Microbial Transplantation; Anti-Inflammatory Diet; Sham transplantation; Sham Diet; Advanced Therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-03-15
    Completion
    2028-03-15
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    InterventionFecal Microbial Transplantation; Anti-Inflammatory Diet; Sham transplantation; Sham Diet +1 more
    PhaseNot applicable
    Registry statusRecruiting

  • Effectiveness of Adding Morphine to Intraosseous Vancomycin for Pain Control in Total Knee Arthroplasty

    NCT06716749 · start 2024-12-01

    Registered record
    Registry ID
    NCT06716749
    Conditions
    Primary Total Knee Arthroplasty; Intraosseous Morphine Injection; Knee Osteoarthritis
    Interventions
    Morphine; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-12-01
    Completion
    2025-06-02
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Total Knee Arthroplasty; Intraosseous Morphine Injection; Knee Osteoarthritis
    InterventionMorphine; Vancomycin
    PhasePhase 2
    Registry statusCompleted

  • Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement

    NCT06814223 · start 2024-10-28

    Registered record
    Registry ID
    NCT06814223
    Conditions
    Infection Catheter-Related
    Interventions
    • Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously. • Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-10-28
    Completion
    2028-06-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Catheter-Related
    Intervention• Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously. • Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA
    PhasePhase 4
    Registry statusRecruiting

  • Pharmacokinetics Vancomycin CVVHDF with OXiris Membrane

    NCT06543940 · start 2024-09-01

    Registered record
    Registry ID
    NCT06543940
    Conditions
    AKI - Acute Kidney Injury
    Interventions
    Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-09-01
    Completion
    2025-12-31
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAKI - Acute Kidney Injury
    InterventionVancomycin
    PhaseNot applicable
    Registry statusRecruiting

  • Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders

    NCT06503978 · start 2024-08-20

    Registered record
    Registry ID
    NCT06503978
    Conditions
    Autism Spectrum Disorder; Gastro-Intestinal Disorder; Constipation; Diarrhea
    Interventions
    MTP-101P; Vancomycin; Miralax; Antacid; Placebo MTP-101P; Placebo Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-08-20
    Completion
    2026-08-17
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorder; Gastro-Intestinal Disorder; Constipation; Diarrhea
    InterventionMTP-101P; Vancomycin; Miralax; Antacid +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Population Pharmacokinetic Model of Amikacin and Vancomycin in Critically Ill Patients

    NCT06261164 · start 2024-01-31

    Registered record
    Registry ID
    NCT06261164
    Conditions
    Sepsis
    Interventions
    Cytosorb® and Oxiris® adsorbents
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-01-31
    Completion
    2025-01-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionCytosorb® and Oxiris® adsorbents
    PhaseNot recorded
    Registry statusUnknown

  • Antibiotics and Vaccine Immune Responses Study

    NCT06148025 · start 2023-11-23

    Registered record
    Registry ID
    NCT06148025
    Conditions
    Vaccine Response Impaired
    Interventions
    BCG vaccine; Yellow Fever vaccine; Vancomycin Oral Capsule; Neomycin Oral Product; Metoclopramide (Maxolon); Loperamide HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-11-23
    Completion
    2028-10-01
    Enrolment
    348

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVaccine Response Impaired
    InterventionBCG vaccine; Yellow Fever vaccine; Vancomycin Oral Capsule; Neomycin Oral Product +2 more
    PhasePhase 4
    Registry statusRecruiting

  • A Dried Blood Spot Sampling Method for Vancomycin and Creatinine Monitoring for OPAT

    NCT06283433 · start 2023-10-25

    Registered record
    Registry ID
    NCT06283433
    Conditions
    Infection, Bacterial
    Interventions
    Finger Prick; Venipuncture
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-10-25
    Completion
    2024-11
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Bacterial
    InterventionFinger Prick; Venipuncture
    PhaseNot applicable
    Registry statusUnknown

  • First Time Right of Vancomycin

    NCT05964114 · start 2023-10

    Registered record
    Registry ID
    NCT05964114
    Conditions
    Vancomycin; Pharmacokinetics
    Interventions
    Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-10
    Completion
    2026-06
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVancomycin; Pharmacokinetics
    InterventionVancomycin
    PhaseNot applicable
    Registry statusUnknown

  • Vancomycin in Primary Sclerosing Cholangitis in Italy

    NCT05876182 · start 2023-06-15

    Registered record
    Registry ID
    NCT05876182
    Conditions
    Primary Sclerosing Cholangitis; Liver and Intrahepatic Bile Duct Disorder; IBD
    Interventions
    Oral Vancomycin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-06-15
    Completion
    2026-06
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Sclerosing Cholangitis; Liver and Intrahepatic Bile Duct Disorder; IBD
    InterventionOral Vancomycin; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC

    NCT04793152 · start 2023-03-20

    Registered record
    Registry ID
    NCT04793152
    Conditions
    MRSA
    Interventions
    Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-03-20
    Completion
    2029-10
    Enrolment
    700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMRSA
    InterventionVancomycin
    PhaseNot applicable
    Registry statusRecruiting

  • Impact of Prophylactic Antibiotics on Bloodstream Infections After Liberation From Extracorporeal Membrane Oxygenation

    NCT05651464 · start 2023-01-01

    Registered record
    Registry ID
    NCT05651464
    Conditions
    Catheter-Related Infections
    Interventions
    Vancomycine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-01-01
    Completion
    2023-12-31
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCatheter-Related Infections
    InterventionVancomycine
    PhaseNot applicable
    Registry statusUnknown

  • Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients

    NCT04246151 · start 2022-09-01

    Registered record
    Registry ID
    NCT04246151
    Conditions
    Clostridium Difficile Colonization; Clostridium Difficile Diarrhea
    Interventions
    Vancomycin; Culturelle; Vancomycin Placebo; Probiotic Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2022-09-01
    Completion
    2024-09-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClostridium Difficile Colonization; Clostridium Difficile Diarrhea
    InterventionVancomycin; Culturelle; Vancomycin Placebo; Probiotic Placebo
    PhaseEarly phase 1
    Registry statusWithdrawn

  • The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study

    NCT05655689 · start 2021-12-31

    Registered record
    Registry ID
    NCT05655689
    Conditions
    Bacterial Keratitis; Fungal Keratitis; Mixed Bacterial and Fungal Keratitis; Microbial Keratitis
    Interventions
    Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution; Ceftazidime 5% + vancomycin 5%; Gentamicin 1.4% + vancomycin 5%; Natamycin 5% Oph Susp; Voriconazole 1%; Natamycin 5% + voriconazole 1%; Natamycin 5%+ ceftazidime 5% + vancomycin 5%; Voriconazole 1% + ceftazidime 5% + vancomycin 5%
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-12-31
    Completion
    2023-01-01
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Keratitis; Fungal Keratitis; Mixed Bacterial and Fungal Keratitis; Microbial Keratitis
    InterventionMoxifloxacin Ophthalmic 0.5% Ophthalmic Solution; Ceftazidime 5% + vancomycin 5%; Gentamicin 1.4% + vancomycin 5%; Natamycin 5% Oph Susp +4 more
    PhaseNot recorded
    Registry statusCompleted